Abstract : IgA nephropathy IgAN is characterized by mesangial deposition of IgA, C3, and often IgM. We examined the relationship among IgM deposition, clinical features, and renal outcome in IgAN patients who underwent combined treatment of tonsillectomy with steroid pulse therapy Tx-SP . We retrospectively reviewed 73 IgAN patients treated with Tx-SP from March 2006 to March 2014. The patients were divided into those with moderate 2 to severe 3 mesangial IgM deposition Prominent IgM-positive patients, P-Group and those with negative to faint 1 deposition the Other patients, O-Group . Using propensity scores to minimize confounding factors, 11 propensity score-matched patients with O-Group mO-Group were compared to 11 P-Group patients. The study out come was de ned as urinary protein grade by urine test strip before Tx-SP and one year after Tx-SP. P-Group patients exhibited an increased severity of protein uria compared to O-Group p 0.018 and mO-Group patients p 0.009 before Tx-SP. After Tx-SP, proteinuria was signi cantly ameliorated in the P-Group, reach ing the same severity recorded in the O-Group p 0.007 and mO-Group p 0.021 . No signi cant differences were noted between P-Group and mO-Group in microhematuria, serum creatinine level, and histological severity. Prominent IgM deposition is associated with severe proteinuria in IgAN. However, Tx-SP induces a suf cient reduction in the severity of proteinuria in IgM-positive IgAN.
Introduction
IgA nephropathy IgAN is the most common lesion causing primary glomerulonephritis in developed countries, and its only clinical manifestation is hematuria or proteinuria [1] [2] [3] [4] [5] [6] [7] [8] . IgAN diagnosis can only be con rmed by kidney biopsy, where pathognomonic ndings on immuno- To whom corresponding should be addressed.
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uorescence microscopy typically show prominent glomerular deposits of IgA often accompanied by C3 and IgG in the mesangium and along the glomerular capillary wall. Proteinuria is a serious risk factor of disease progression in IgAN patients 9 . While two general approaches have been developed to slow such progression -namely blood pressure control using angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and therapy with glucocorticoids 10 -combined treatment of tonsillectomy with steroid pulse therapy Tx-SP has been reported to induce clinical remission of IgAN, representing a more promising, proactive therapy 11 .
Despite progress, the indications for Tx-SP remain unclear. Differences in disease severity and the presence of multiple subtypes of IgAN have been observed, with some reports of patients with IgM-positive IgAN having more severe proteinuria than those with IgM-negative IgAN. Further study to corroborate these claims is necessary 12 13 .
Here, we compared the clinical features of Prominent IgM-positive ≥ 2 intensity IgAN patients with other IgAN patients and evaluated the clinical response to Tx-SP treatment in both groups.
Methods

Study design and patients
Our retrospective cohort study was conducted from March 2006 to March 2014, and approved by the Showa University Fujigaoka Hospital Institutional Review Board.
A total of 119 patients aged 16 years or older were diagnosed with IgAN at Showa University Fujigaoka Hospital, and received a combined treatment of tonsillectomy with steroid pulse therapy Tx-SP . IgAN was diagnosed based on light microscopy ndings of mesangial proliferative changes, immuno uorescence IF ndings of mesangial IgA and C3 deposition, and electron microscopy ndings of electron-dense deposits in glomerular mesangial tissue obtained by renal biopsy. Of the initial 119 patients, 46 were excluded from the study due to more than a year lapsing between renal biopsy and Tx-SP or for having a history of systemic disease, such as diabetes mellitus, systemic lupus erythematosus, severe infection, or secondary IgAN. Clinical parameters of the 73 patients without missing data are shown in Table 1 and include age, sex, medication history, qualitative urinary protein UP level, urinary red blood cell U-RBC count, serum creatinine sCr levels, and estimated glomerular ltration rate eGFR ; calculated using the Modi cation of Diet in Renal Disease formula for Japanese. eGFR 186.3 sCr Qualitative urinary protein level was converted to a score using a urine test strip as follows : negative / Grade 0, 1 / Grade 1, 2 / Grade 2, and ≥ 3 / Grade 3. U-RBC count was also converted into a score based on the number of red blood cells in a high-power eld x400 as follows : none-4 / Grade 0, 5-9 / Grade 1, 10-29 / Grade 2, and ≥ 30 / Grade 3. All clinical parameters were measured at two points. Baseline data were collected at the time of hospitalization for the purpose of renal biopsy Before and follow-up data were collected in the outpatient section at one year after the start of Tx-SP After .
The Tx-SP protocol states that, for tonsillectomy, the tonsils are to be examined by an otorh-inolaryngologist during surgery after obtaining informed consent , regardless of the gross appearance of the tonsils and even in the absence of episodes of recurrent tonsillitis or gross hematuria with tonsillitis 14 . During the rst year after tonsillectomy, Tx-SP should be administered as follows : high-dose methylprednisolone 0.5 g / day 3 times a week for 3 consecutive weeks , followed by oral prednisolone at an initial dose of 30 mg every other day, with gradual tapering of the dose over the course of 1 year. The study outcome was de ned as urinary protein grade by urine test strip before Tx-SP and one year after Tx-SP.
Pathological analysis
Renal tissue samples obtained by percutaneous needle biopsy were divided into three portions, which were processed separately for study by light, IF, and electron microscopy, respectively, using standard techniques. For light microscopy, the renal tissue samples were xed in 4 % buffered formaldehyde, embedded in Paraplast, and stained with hematoxylin and eosin, periodic acidSchiff, periodic acid methenamine silver, and Masson s trichrome. For IF microscopy, the renal tissue samples were frozen in liquid nitrogen, and cryostat sections were stained with uorescein isothiocyanate-labeled antisera to human IgA, IgG1, IgG4, IgM, kappa and lambda light chains, C3, C1q, C4, and brinogen. The histologic severity was graded using Clinical Guides for IgA Nephropathy in Japan, third version 15 . Immuno uorescence staining level was converted into a score of immunoglobulin deposition in the mesangial matrix, as follows : Grade 0 : -, Grade 1 : , Grade 2 :
, Grade 3 : . 
Statistical analysis
We used a matched cohort approach based on the presence of IgM deposition in IgAN patients to minimize the influence of confounding factors. Propensity score matching is a method of adjusting for the observed characteristics of non-randomly assigned patients 16 . In this study, we matched the number of moderate 2 to severe 3 mesangial IgM deposition patients collectively Prominent IgM-positive patients with negative to faint 1 mesangial IgM deposition patients collectively the other patients after calculating a propensity score for each patient. We derived the propensity score from a multilogistic regression model containing the following variables : age, sex, and medication history. Propensity scoring analysis was used to adjust for selection bias. In this way, patients were divided into three groups according to mesangial deposition : Prominent IgM-positive patients P-Group : n 11 , the Other patients O-Group : n 62 , and propensity score-matched patients Prominent IgMpositive patients with the other patients ; mO-Group : n 11 .
Results are expressed as either mean standard deviation or as a percentage. Nonparametric variables were compared using the Mann-Whitney U test, while categorical variables were compared using Fisher s exact test. P-values less than 0.05 were considered statistically signi cant. Results were analyzed using JMP Pro 11.0.0 SAS Institute Inc., Cary, NC, USA .
Results
The characteristics of the three groups are summarized and compared in Table 2 . Age, sex, urine RBC, sCr, and eGFR were comparable among the three groups. However, UP grade was higher in the P- Table 3 details the pathological features of the Prominent IgM-positive and matched patients. No marked histological differences were noted between the P-Group and mO-Group, including histological severity grade 1 / 2 / 3 / 4 : 5 / 4 / 1 / 1 vs. 5 / 4 / 1 / 1, p 1.000. There was also no signi cant difference between P-Group and mO-Group in the mesangial deposition of IgG and C1q, a parameter that has been associated with renal dysfunction in previous studies 17 18 .
Discussion
In the present study, we examined the effect of Tx-SP on proteinuria in IgAN patients independent of glomerular prominent IgM deposition levels. Prominent IgM deposition in the glomerulus was associated with severe proteinuria in patients with IgAN, despite a lack of marked differences in histological severity grade between patients with and without prominent IgM deposition. We also noted a decrease in urinary protein excretion in Prominent IgM-positive patients after Tx-SP to levels similar to those observed in the other patients. Persistent proteinuria is a risk factor for poor prognosis in renal function 9 19 , thus we expect that Tx-SP could improve the We suspect that Prominent IgM-positive IgA nephropathy patients may be at risk of developing not only size selectivity disorder due to glomerulus capillaritis, but also charge selectivity disorder, as recorded with nephrotic syndromes such as MCD and FSGS. These suspicions are based on the fact that initial proteinuria showed the only difference in clinical parameters and degree of histological damage on renal biopsy between the P-Group and mO-Group in the present study. Several limitations to our study warrant mention. First, proteinuria was evaluated qualitatively, rather than quantitatively, due to quantitative data not being measured at all time points based on the physician s decision. Urinary protein quantitative data are generally measured at the time of hospitalization for the purpose of renal biopsy, but only rarely in outpatients after Tx-SP. Therefore we could not use the data we had in this analysis Table 4 . Second, we only assessed the presence of glomerular lesions in our histological evaluation, not framework disorder, as our histological evaluation referenced renal biopsy evaluation results and was conducted by the attending physician based on medical records, thereby preventing observer bias. Oxford categorization criteria were established in 2009, and no stromal evaluation was conducted before that point. We therefore used Clinical Guides for IgA Nephropathy in Japan, third version 15 to describe histological disease severity. Third, Tx-SP was performed in this study, but steroid pulse therapy alone might be effective. We believe that the severe proteinuria observed in Prominent IgM-positive IgAN is due to the presence of charge selectivity disorder, similar to that observed with nephrotic syndrome. Because steroid therapy itself is a treatment modality of nephrotic syndrome, tonsillectomy may not be necessary. Future investigations should take these three points into account. In conclusion, prominent IgM deposition in glomerulus is associated with severe proteinuria in patients with IgAN. Our study con rms that Tx-SP induces a marked reduction of proteinuria severity in Prominent IgM-positive IgAN patients and may therefore represent a powerful therapeutic strategy in this particular patient population. 
